Tilray Brands, Inc. (FRA:2HQ0)
Germany · Delayed Price · Currency is EUR | Market Cap | 889.67M |
| Revenue (ttm) | 710.22M |
| Net Income (ttm) | -1.84B |
| Shares Out | n/a |
| EPS (ttm) | -19.68 |
| PE Ratio | n/a |
| Forward PE | 132.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70 |
| Average Volume | 8,521 |
| Open | 7.80 |
| Previous Close | 7.89 |
| Day's Range | 7.76 - 7.87 |
| 52-Week Range | 2.99 - 19.50 |
| Beta | n/a |
| RSI | 43.27 |
| Earnings Date | Jan 8, 2026 |
About Tilray Brands
Tilray Brands, Inc., a lifestyle consumer products company, engages in the research, cultivation, processing, and distribution of medical cannabis products in Canada, the United States, Europe, the Middle East, Africa, and internationally. The company operates through four segments: Beverage, Cannabis, Distribution, and Wellness. It also offers medical and adult-use cannabis products; resells and distributes pharmaceutical and wellness products; and produces, markets, and sells beverage products, and hemp-based food products. In addition, the c... [Read more]
Financial Performance
In 2025, Tilray Brands's revenue was $821.31 million, an increase of 4.10% compared to the previous year's $788.94 million. Losses were -$2.19 billion, 792.6% more than in 2024.
Financial numbers in USD Financial StatementsNews
Trump Is Warming to Cannabis, but Investors Aren't Impressed
Stocks took a surprise tumble after the White House moved to reclassify marijuana as a less dangerous drug.
2 Marijuana Stocks To Watch For Better Investing In 2026
The cannabis industry continues evolving into a bigger and more regulated global market. Legalization trends are expanding across the United States and international regions. This growth fuels long-te...
I Was Right: President Trump Will Legalize Marijuana in 2026
President Trump has ordered that marijuana be reclassified as a Schedule III drug. The move doesn't fully legalize marijuana -- yet -- but it may foreshadow changes to come.
3 Marijuana Stocks To Watch In 2026
The cannabis industry is entering another critical growth phase, positioning 2026 as a potentially pivotal year. Particularly for long-term investors looking to make a profit with marijuana stocks. Af...
Marijuana Stocks To Watch After The Holidays
In 2026, the impact of cannabis rescheduling is expected to be far more visible in marijuana stock performance. Much more than in the initial announcement of cannabis becoming a Class 3 substance. Whi...
Is Tilray Stock's 25% Drop An Opportunity Or Trap?
Tilray Brands (TLRY) stock has declined by 25.3% in under a month, decreasing from $13.94 on 16th Dec, 2025 to $10.53 currently. Is it time to purchase this dip?
This Stock Has Almost Tripled in 6 Months. Here's What Investors Need to Watch Next
Tilray's shares have soared since mid-2025, driven by expectations of cannabis reclassification in the U.S. These expectations have now become a reality, and they will have an impact on pot growers in...
President Trump Just Reclassified Marijuana. Are Green Thumb, Tilray, and Trulieve Stocks No-Brainer Buys?
Trump's executive order to reclassify marijuana from Schedule I to Schedule III recognized the valid medical uses of the drug. The move could impact cannabis companies in several ways, including allow...
3 Top Marijuana Stocks After Cannabis Gets Rescheduled
Donald Trump's recent executive order moving cannabis off Schedule I marks a pivotal moment for the U.S. cannabis sector. While the order does not legalize marijuana at the federal level, rescheduling...
Tilray Brands to Announce Second Quarter Fiscal Year 2026 Financial Results on January 8, 2026
NEW YORK and LEAMINGTON, Ontario, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at...
Inside the dealmaking that pushed Trump to reclassify pot, expand access
President Donald Trump's marijuana reclassification executive order followed a yearlong push by cannabis executives, billionaire allies and political operatives combining donations, lobbying and targe...
After Trump's move to reclassify cannabis, here's what Wall Street is thinking
Analysts are now focused on the when the change will actually happen, as the cannabis industry waits for tax relief and expanded research opportunities.
Is Tilray Brands Stock a Buy, Sell, or Hold in 2026?
Tilray Brands' stock performance hinges on the outlook for marijuana reform in the U.S. President Trump is considering rescheduling marijuana, which has investors bullish on Tilray of late. The compan...
Why Tilray Stock Dropped This Week, Even After President Trump's Executive Order
Investors felt the cannabis executive order didn't go far enough. Tilray's CEO backed President Trump's decision, but called it an "incremental step.
Trump signs executive order to reschedule cannabis. Here's what's next
Trump's executive order shifts cannabis from Schedule I to Schedule III, and launches a Medicare pilot program for CBD products. Brandon Gomez unpacks what's next, the hurdles ahead and what shifted t...
Trump just legalized marijuana nationwide — here's why potheads are rejoicing
As On The Money has been reporting since April, our famously drug-and-drink-averse president has been inching ever closer to making marijuana significantly less criminal in the eyes of the federal gov...
Trump sparks market shock with MAJOR marijuana move
Rep. Greg Steube, R-Fla., joins ‘Mornings with Maria' to discuss cutting healthcare costs, the fight over Obamacare subsidies and shutdown risks, President Donald Trump's marijuana order and the GOP's...
Former WH drug policy advisor: Mass commercialization and promotion of marijuana isn't a good thing
Kevin Sabet, Smart Approaches to Marijuana CEO, former White House drug policy advisor and ‘One Nation Under Influence' author, joins 'Squawk Box' to discuss President Trump's executive order to recla...
Why US banks are still wary of cannabis despite Trump's policy shift
President Donald Trump's move to relax federal marijuana regulations has been welcomed by the US cannabis industry, but it has not changed the sector's most persistent challenge. Access to mainstream ...
How Trump's marijuana reclassification could impact medical research
Scotts Miracle-Gro CEO James Hagedorn discusses President Donald Trump signing an executive order to reclassify marijuana on ‘The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #brea...
Cannabis companies face hurdles accessing big banks despite reclassification, experts say
U.S. President Donald Trump's move to relax marijuana regulations could ease some burden for cannabis companies, but will likely keep doors to access capital from big banks closed, experts said.
Trulieve CEO Kim Rivers reacts to marijuana being reclassified
Trulieve Founder, Chair, and CEO Kim Rivers joins 'Fast Money' with reaction to Pres. Trump reclassifying marijuana.
Stock Market Today, Dec. 18: Tilray Brands Jumps After Trump Order Spurs Cannabis Rescheduling
Expand NASDAQ: TLRY Tilray Brands Today's Change (-4.04%) $-0.52 Current Price $12.36 Key Data Points Market Cap $1.5B Day's Range $12.10 - $15.68 52wk Range $3.51 - $23.20 Volume 1.5M Avg Vol 10M Gro...
Trump signed an executive order to reclassify marijuana.
About Yahoo Finance: Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage ...
Trump signs order to expedite marijuana reschedules, Kevin Hassett vs. Kevin Warsh in Fed chair race
Market Domination Overtime anchor Josh Lipton breaks down the latest market moves for December 18, 2025. President Trump signed an executive order today to expedite the rescheduling of marijuana.